Abstract
Hereditary leiomyomatosis and renal cell cancer (HLRCC) (MIM 605839) is a recently identified autosomal dominant tumor susceptibility syndrome characterized by predisposition to benign leiomyomas of the skin and the uterus (fibroids, myomas). Susceptibility to early-onset renal cell carcinoma and uterine leiomyosarcoma is present in a subset of families. Renal cell carcinomas are typically solitary and aggressive tumors displaying papillary type 2 or collecting duct histology. The disease predisposing gene was identified as fumarate hydratase (fumarase, FH) (MIM 136850). FH encodes an enzyme that operates in the mitochondrial Krebs cycle being thus involved in cellular energy metabolism. The recent discovery of HLRCC and the predisposing gene FH has increased the present knowledge of hereditary renal cancer and enabled identification of the predisposed individuals. This review provides the present knowledge of the clinical, histopathological, and molecular features of HLRCC. Future prospects related to studies on the phenotype and molecular biology of HLRCC will also be discussed.
Keywords: hlrcc, fh, fumarase, leiomyoma, leiomyosarcoma, renal cancer
Current Molecular Medicine
Title: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Volume: 4 Issue: 8
Author(s): Maija Kiuru and Virpi Launonen
Affiliation:
Keywords: hlrcc, fh, fumarase, leiomyoma, leiomyosarcoma, renal cancer
Abstract: Hereditary leiomyomatosis and renal cell cancer (HLRCC) (MIM 605839) is a recently identified autosomal dominant tumor susceptibility syndrome characterized by predisposition to benign leiomyomas of the skin and the uterus (fibroids, myomas). Susceptibility to early-onset renal cell carcinoma and uterine leiomyosarcoma is present in a subset of families. Renal cell carcinomas are typically solitary and aggressive tumors displaying papillary type 2 or collecting duct histology. The disease predisposing gene was identified as fumarate hydratase (fumarase, FH) (MIM 136850). FH encodes an enzyme that operates in the mitochondrial Krebs cycle being thus involved in cellular energy metabolism. The recent discovery of HLRCC and the predisposing gene FH has increased the present knowledge of hereditary renal cancer and enabled identification of the predisposed individuals. This review provides the present knowledge of the clinical, histopathological, and molecular features of HLRCC. Future prospects related to studies on the phenotype and molecular biology of HLRCC will also be discussed.
Export Options
About this article
Cite this article as:
Kiuru Maija and Launonen Virpi, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC), Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359638
DOI https://dx.doi.org/10.2174/1566524043359638 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Calcium as a Molecular Target in Angiogenesis
Current Pharmaceutical Design Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Current Drug Targets Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Annexins Bend Wound Edges during Plasma Membrane Repair
Current Medicinal Chemistry Anionic Linear Globular Dendrimer-G2-Ciprofloxacin Nano-Conjugate: Novel Agent against Wilson Disease Cell Model
Letters in Drug Design & Discovery